Claims for Patent: 9,877,962

Summary for Patent: 9,877,962

Title:	Piperazinyl derivatives for the treatment of cancer
Abstract:	Piperazinyl derivatives of formula (I) and their use as a drug, particularly for the treatment of cancer, are disclosed. Also disclosed are pharmaceutical compositions comprising the piperazinyl derivatives, and methods for synthesizing the piperazinyl derivatives.
Inventor(s):	Carniato; Denis (Marcoussis, FR), Briand; Jean-Francois (Saclay, FR), Gutmann; Mathieu (Vaugrigneuse, FR), Busnel; Olivier (Allennes les Marais, FR), Bougeret; Cecile (Nevers, FR), Deprez; Benoit (Lille, FR), Jaillardon; Karine (Saint Michel s/Orge, FR)
Assignee:	Pitty; Marc Henry (Boulogne-Billancourt, FR)
Application Number:	15/135,994
Patent Claims:	1. A method for the treatment of cancer comprising the administration to a person in need thereof of an efficient amount of a compound of following general formula (I): ##STR00062## or a pharmaceutically acceptable salt thereof, a stereoisomer or a mixture of stereoisomers in any proportion, where: X is a (C.sub.1-C.sub.6)alkyl, phenyl, benzyl, C(O)OR5 or C(O)NHR5 group; R1 is a hydrogen atom or a C(O)H, C(O)R6 or C(O)OR6 group; R2 is a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group; or R2 together with R1 or X forms a saturated hydrocarbon chain to form a 5- or 6-membered ring; R3 is a hydrogen or halogen atom or a (C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkoxy group; R4 is a hydrogen or halogen atom, CN, NO.sub.2, or a (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy, aryloxy, benzyloxy or heteroaryloxy group, the said group optionally being substituted by one or more halogen atoms; Ar is a thiophenyl group or a phenyl group optionally substituted by one or more halogen atoms; and R5 and R6 independently of one another are a (C.sub.1-C.sub.6)alkyl, aryl-(C.sub.1-C.sub.6)alkyl or aryl group, the said group optionally being substituted by one or more halogen atoms, wherein the cancer is selected from the group consisting of melanoma, lung cancer, CNS cancer, prostate cancer, renal cancer, head and neck cancer, and hepatocarcinoma. 2. The method according to claim 1, wherein the compound has the following formula (I-bis): ##STR00063## 3. The method according to claim 1, wherein Ar is a thiophenyl group or a phenyl group substituted by one or more fluorine atoms. 4. The method according to claim 3, wherein Ar is a thiophenyl group or a 4-fluoro-phenyl group. 5. The method according to claim 1, wherein R4 is a hydrogen or halogen atom or a (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy or aryloxy group, the said group optionally being substituted by one or more halogen atoms. 6. The method according to claim 1, wherein R3 is a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group. 7. The method according to claim 1, wherein X is a (C.sub.1-C.sub.6)alkyl, phenyl or benzyl group; R1 and R2 are a hydrogen atom; R3 is a hydrogen atom or a (C.sub.1-C.sub.6)alkyl group; R4 is a halogen atom or a (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6)alkoxy, aryloxy or benzyloxy group, the said group optionally being substituted by one or more halogen atoms; Ar is a thiophenyl group or a phenyl group optionally substituted by a fluorine atom; and R5 and R6 independently of one another are a (C.sub.1-C.sub.6)alkyl, aryl-(C.sub.1-C.sub.6)alkyl or aryl group, the said group optionally being substituted by one or more fluorine atoms. 8. The method according to claim 1, wherein the compound is selected from among: ##STR00064## ##STR00065## ##STR00066## ##STR00067## ##STR00068## ##STR00069## ##STR00070## ##STR00071## ##STR00072## ##STR00073## ##STR00074## ##STR00075## ##STR00076## ##STR00077## ##STR00078## ##STR00079## ##STR00080## ##STR00081## ##STR00082## ##STR00083## ##STR00084## ##STR00085## ##STR00086## ##STR00087## ##STR00088## ##STR00089## ##STR00090## ##STR00091## ##STR00092## ##STR00093## 9. The method according to claim 1, wherein the cancer is a chemotherapy-resistant cancer. 10. A method for the treatment of cancer comprising the administration to a person in need thereof of an efficient amount of a pharmaceutical composition comprising at least one compound of general formula (I) according to claim 1 in association with one or more pharmaceutically acceptable excipients, wherein the cancer is selected from the group consisting of melanoma, lung cancer, CNS cancer, prostate cancer, renal cancer, head and neck cancer and hepatocarcinoma. 11. The method according to claim 10, wherein the pharmaceutical composition comprises at least one other active ingredient. 12. The method according to claim 11, wherein the at least one other active ingredient is an anticancer agent. 13. The method according to claim 12, wherein the at least one other active ingredient is chosen from among cisplatin and its derivatives; taxanes, paclitaxel and docetaxel; vinca alkaloids; purine analogues s; topoisomerase I inhibitors; topoisomerase II inhibitors; anti-tumour nucleoside derivatives; alkylating agents; derivatives of anti-tumour anthracyclines; molecules targeting the IGF-I receptor; tetracarcin derivatives; corticosteroids; antibodies; antagonists or selective modulators of oestrogen receptors; aromatase inhibitors; differentiating agents; DNA methyl-transferase inhibitors; antifolates; antibiotics; antimetabolites; apoptosis-inducing agents and anti-angiogenic agents of Bcl-2 inhibitors; agents binding to tubulin; kinase inhibitors; farnesyl transferase inhibitors; histone-deacetylase inhibitors; inhibitors of the ubiquitin-proteasome system; and telomerase inhibitors. 14. The method according to claim 13, wherein the cisplatin derivatives are chosen among carboplatin and oxalyplatin; the taxanes are chosen among taxol, taxotere, paclitaxel and docetaxel; the vinca alkaloids are chosen among vinblastine, vincristine and vinorelbine; the purine analogues are chosen among mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine; the topoisomerase I inhibitors are chosen among camptothecin compounds; the topoisomerase II inhibitors are chosen among epipodophyllotoxin, podophyllotoxin and the derivatives thereof; the anti-tumour nucleoside derivatives are chosen among 5-fluorouracil, leucovorin, gemcitabine and capecitabine; the alkylating agents are chosen among nitrogen mustards, nitroso-ureas, alkylsulfonates, ethylenimines, methylmelamines and tetrazines; the derivatives of anti-tumour anthracyclines are chosen among daunorubicin, adriamycin, doxil, idarubicin and mitoxantrone; the molecule targeting the IGF-I receptor is picropodophyllin; the tetracarcin derivative is tetrocarcin A; the corticosteroid is prednisone; the antibodies are chosen among trastuzumab (anti-HER2 antibody), rituximab (anti-CD20 antibody), gemtuzamab, cetuximab, pertuzumab and bevacizumab; the antagonists or selective modulators of oestrogen receptors are chosen among tamoxifen, fulvestrant, toremifene, droloxifene, faslodex and raloxifene; the aromatase inhibitors are chosen among exemestane, anastrozole, letrozole and vorozole; the differentiating agents are chosen among retinoids and agents blocking the metabolism of retinoic acid; the DNA methyl-transferase inhibitors are chosen among azacytidine and decitabine; the antifolate is permetrexed disodium; the antibiotics are chosen among antinomycin D, bleomycin, mitomycin C, actinomycin D, carminomycin, daunomycin and plicamycin; the antimetabolites are chosen among chlofarabine, aminopterin, cytosine arabinoside, floxuridine and methotrexate; the apoptosis-inducing agents and anti-angiogenic agents of Bcl-2 inhibitors are chosen among 2-methoxycarbonylamino-4-methylsulfanyl-butyric acid, 4-(4,9-dioxo-4,9-dihydronaphtho[2,3-d]thiazol-2-ylamino)-phenyl-ester, 4-[4-[(4'-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)-- 3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfon- yl]benzamide, gossypol, 2-amino-6-bromo-.alpha.-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid, ethyl ester, N-[4-[[2-(1,1-Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[- 2-(1-methylethyl)phenyl]methyl]benzamide and decanoic acid; the agents binding to tubulin are chosen among combrestatin, colchicine derivatives and nocodazole; the kinase inhibitors are chosen among flavoperidol, imatinib mesylate, erlotinib and gefitinib; the farnesyl transferase inhibitor is tipifarnib; the histone-deacetylase inhibitors are chosen among sodium butyrate, suberoylanilide hydroxamic acid, depsipeptide, dacinostat, N-hydroxy-2-(4-(naphthalen-2-ylsulfonyl)piperazin-1-yl)pyrimidine-5-carbo- xamide, quisinostat and trichostatin A; the inhibitors of the ubiquitin-proteasome system are chosen among bortezomib, bortezomib and yondelis; and the telomerase inhibitor is telomestatin. 15. The method according to claim 14, wherein the camptothecin compounds are chosen among irinotecan and topotecan; the podophyllotoxin derivatives are chosen among etoposide and teniposide; the nitrogen mustards are chosen among cyclophosphamide, mechlorethamine, chlorambucil and melphalan; the nitroso-ureas are chosen among carmustin, lomustin and streptozocin; the alkylsulfonate is busulfan; the ethylenimines and methylmelamines are chosen among thiotepa and hexamethylmelamine; the tetrazine is dacarbazine; the retinoids are chosen among retinoic acid and vitamin D; and the agent blocking the metabolism of retinoic acid is Isoretinoin. 16. A method for the treatment of cancer comprising the administration to a person in need thereof of an efficient amount of a pharmaceutical composition comprising: (i) at least one formula (I) compound according to claim 1; and (ii) at least one other active ingredient, as combination products for simultaneous, separate or time-staggered use thereof, wherein the cancer selected from the group consisting of melanoma, lung cancer, CNS cancer, prostate cancer, renal cancer, head and neck cancer and hepatocarcinoma. 17. The method according to claim 16, wherein the at least one other active ingredient is an anticancer agent. 18. The method according to claim 17, wherein the at least one other active ingredient is selected from among cisplatin and the derivatives thereof; taxanes; vinca alkaloids; purine analogues; topoisomerase I inhibitors; topoisomerase II inhibitors; anti-tumour nucleoside derivatives; alkylating agents; derivatives of anti-tumour anthracyclines; molecules targeting the IGF-I receptor; tetracarcin derivatives; corticosteroids; antibodies; antagonists or selective modulators of oestrogen receptors; aromatase inhibitors; differentiating agents; DNA methyl-transferase inhibitors; antifolates; antibiotics; antimetabolites; apoptosis-inducing agents and anti-angiogenic agents of Bcl-2 inhibitors; agents binding to tubulin; kinase inhibitors; farnesyl transferase inhibitors; histone-deacetylase inhibitors; inhibitors of the ubiquitin-proteasome system s; and telomerase inhibitors. 19. The method according to claim 18, wherein the cisplatin derivatives are chosen among carboplatin and oxalyplatin; the taxanes are chosen among taxol, taxotere, paclitaxel and docetaxel; the vinca alkaloids are chosen among vinblastine, vincristine and vinorelbine; the purine analogues are chosen among mercaptopurine, thioguanine, pentostatin and 2-chlorodeoxyadenosine; the topoisomerase I inhibitors are chosen among camptothecin compounds; the topoisomerase II inhibitors are chosen among epipodophyllotoxin, podophyllotoxin and the derivatives thereof; the anti-tumour nucleoside derivatives are chosen among 5-fluorouracil, leucovorin, gemcitabine and capecitabine; the alkylating agents are chosen among nitrogen mustards, nitroso-ureas, alkylsulfonates, ethylenimines, methylmelamines and tetrazines; the derivatives of anti-tumour anthracyclines are chosen among daunorubicin, adriamycin, doxil, idarubicin and mitoxantrone; the molecule targeting the IGF-I receptor is picropodophyllin; the tetracarcin derivative is tetrocarcin A; the corticosteroid is prednisone; the antibodies are chosen among trastuzumab (anti-HER2 antibody), rituximab (anti-CD20 antibody), gemtuzamab, cetuximab, pertuzumab and bevacizumab; the antagonists or selective modulators of oestrogen receptors are chosen among tamoxifen, fulvestrant, toremifene, droloxifene, faslodex and raloxifene; the aromatase inhibitors are chosen among exemestane, anastrozole, letrozole and vorozole; the differentiating agents are chosen among retinoids and agents blocking the metabolism of retinoic acid; the DNA methyl-transferase inhibitors are chosen among azacytidine and decitabine; the antifolate is permetrexed disodium; the antibiotics are chosen among antinomycin D, bleomycin, mitomycin C, actinomycin D, carminomycin, daunomycin and plicamycin; the antimetabolites are chosen among chlofarabine, aminopterin, cytosine arabinoside, floxuridine and methotrexate; the apoptosis-inducing agents and anti-angiogenic agents of Bcl-2 inhibitors are chosen among 2-methoxycarbonylamino-4-methylsulfanyl-butyric acid, 4-(4,9-dioxo-4,9-dihydronaphtho[2,3-d]thiazol-2-ylamino)-phenyl-ester, 4-[4-[(4 `-Chloro[1,1'-biphenyl]-2-yl)methyl]-1-piperazinyl]-N-[[4-[[(1R)- -3-(dimethylamino)-1-[(phenylthio)methyl]propyl]amino]-3-nitrophenyl]sulfo- nyl]benzamide, gossypol, 2-amino-6-bromo-.alpha.-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid, ethyl ester, N-[4-[[2-(1,1-Dimethylethyl)phenyl]sulfonyl]phenyl]-2,3,4-trihydroxy-5-[[- 2-(1-methylethyl)phenyl]methyl]benzamide and decanoic acid; the agents binding to tubulin are chosen among combrestatin, colchicine derivatives and nocodazole; the kinase inhibitors are chosen among flavoperidol, imatinib mesylate, erlotinib and gefitinib; the farnesyl transferase inhibitor is tipifarnib; the histone-deacetylase inhibitors are chosen among sodium butyrate, suberoylanilide hydroxamic acid, depsipeptide, dacinostat, N-hydroxy-2-(4-(naphthalen-2-ylsulfonyl)piperazin-1-yl)pyrimidine-5-carbo- xamide, quisinostat and trichostatin A; the inhibitors of the ubiquitin-proteasome system are chosen among bortezomib, bortezomib and yondelis; and the telomerase inhibitor is telomestatin. 20. The method according to claim 19, wherein the camptothecin compounds are chosen among irinotecan and topotecan; the podophyllotoxin derivatives are chosen among etoposide and teniposide; the nitrogen mustards are chosen among cyclophosphamide, mechlorethamine, chlorambucil and melphalan; the nitroso-ureas are chosen among carmustin, lomustin and streptozocin; the alkylsulfonate is busulfan; the ethylenimines and methylmelamines are chosen among thiotepa and hexamethylmelamine; the tetrazine is dacarbazine; the retinoids are chosen among retinoic acid and vitamin D; and the agent blocking the metabolism of retinoic acid is Isoretinoin.

Details for Patent 9,877,962

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2031-12-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2031-12-30
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2031-12-30